TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22832260
Drug: Bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent rLP2086 vaccine (60, 120, or 200 μg)
Study: 22832260
Drug: Bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent rLP2086 vaccine
Study: 12948311
Drug: 0.5% piroxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% piroxicam ophthalmic solution
Study: 12948311
Drug: 0.1% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% diclofenac sodium ophthalmic solution
Study: 8831918
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ciprofibrate/day
Study: 8831918
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ciprofibrate/day
Study: 8831918
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fenofibrate HB/day
Study: 1403397
Drug: Dexamethasone, 0.25
Normalized name: Dexamethasone, 0.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 0.25 mg/kg per dose, every 8 hours for a total of three doses
Study: 4059871
Drug: Tobramycin injections
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin injections every 8 hours (TID) for 4 days followed by every 12 hours (BID)
Study: 4059871
Drug: Tobramycin injections
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin injections every 12 hours (BID) for 4 days followed by every 8 hours (TID)
Study: 2979067
Drug: Morphine sulfate,
Normalized name: Morphine Sulfate, 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine sulfate, 5 to 10 mg IV
Study: 2979067
Drug: Meperidine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine, 25 to 50 mg IV
Study: 27888575
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (2 g infusion)
Study: 25500574
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (0.5 mg/kg)
Study: 23040523
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g T gel daily (75 mg delivered)
Study: 19087606
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao capsules (prophylactic oral administration for 3 days before operation)
Study: 19087606
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no Yunnan Baiyao administration)
Study: 16491236
Drug: Fibroblasts from
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibroblasts from normal Tenon capsule
Study: 3511933
Drug: Phenobarbitone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (50 mg for 10 days)
Study: 3511933
Drug: Flumecinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumecinol (200 mg and 600 mg for 6 days)
Study: 3511933
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg for 6 days)
Study: 27439969
Drug: Distal colonic
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal colonic acetate infusion (180 mmol/l)
Study: 27439969
Drug: Distal colonic
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal colonic acetate infusion (100 mmol/l)
Study: 27439969
Drug: Proximal colonic
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal colonic acetate infusion
Study: 30220293
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed generic formulation of abiraterone acetate (250 mg)
Study: 30220293
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation of abiraterone acetate (Zytiga, 250 mg)
Study: 2405727
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimonate (Glucantime), 850 mg antimony/day im for 15 days
Study: 2405727
Drug: Localized controlled
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized controlled heat, 50 degrees C for 30 sec, 3 treatments at 7 day intervals
Study: 6990946
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam every six hours for 48 hours
Study: 22742578
Drug: Paracetamol 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4000 mg q.d.s.
Study: 22742578
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg q.d.s.
Study: 22742578
Drug: Paracetamol 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4000 mg q.d.s. and Aspirin 325 mg q.d.s.
Study: 20378868
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate infusion
Study: 17356283
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for comorbid anxiety disorder
Study: 17356283
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment alone
Study: 7865625
Drug: Anti-tumour-associated glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumour-associated glycoprotein 72 antibody B72.3
Study: 24829088
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml glucose drink (200 kcal)
Study: 24829088
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion at 4 kcal/min into the proximal Roux-limb
Study: 24829088
Drug: 4 kcal/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 kcal/min duodenal infusion (control group)
Study: 22689678
Drug: Post‐consolidation immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐consolidation immunotherapy with histamine dihydrochloride and interleukin‐2
Study: 22689678
Drug: Histamine H(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H(2) receptor expression
Study: 16087995
Drug: 8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/d of a mixed short and long degree of polymerization inulin-type fructan product (fructan group)
Study: 9036741
Drug: Heparin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin for ≤ 48 hours (group 1)
Study: 9036741
Drug: Heparin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin for > 48 hours (group 2)
Study: 1677818
Drug: Atracurium (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.3 mg/kg for <10 kg, 0.5 mg/kg for >10 kg)
Study: 1677818
Drug: Vecuronium (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.05 mg/kg for <10 kg, 0.1 mg/kg for >10 kg)
Study: 7011037
Drug: Debridement and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement and 3% acyclovir ointment
Study: 24793535
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rhPTH(1‐34) (10, 20, 30, 40, 50, or 60 μg)
Study: 24793535
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of rhPTH(1‐34) (10 and 20 μg once daily for 7 consecutive days)
Study: 24793535
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rhPTH(1‐34) (10, 20, or 40 μg)
Study: 24793535
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of rhPTH(1‐34) (20 μg)
Study: 22551909
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d plus OAT with warfarin (C + OAT)
Study: 22551909
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with clopidogrel 75 mg/d plus aspirin 100 mg/d (C + ASA)
Study: 15457467
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg twice a day (n = 104)
Study: 11404671
Drug: ORAL (0.45%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL (0.45% NaCl) equal to 50% of prior dehydration
Study: 10791876
Drug: AIDSVAX (MN)
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX (MN) vaccine (300 microg of MN-rgp120 in alum)
Study: 7598995
Drug: Amoxicillin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (control group) for 4 weeks
Study: 306010
Drug: Whole gut
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole gut irrigation (w.g.i.)
Study: 306010
Drug: Whole gut
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole gut irrigation (w.g.i.) for removal of blood from the intestinal tract
Study: 31686817
Drug: Optimized DPX-loaded
Normalized name: DPX-Survivac
DrugBank: Maveropepimut-S (DB17339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized DPX-loaded nanoparticles (30 mg single oral dose)
Study: 31686817
Drug: Marketed DPX
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed DPX tablet
Study: 15531304
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular hypotensive medication (nonselective beta-blocker or prostaglandin analog)
Study: 10093291
Drug: Bivalent Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent Hib and hepatitis B vaccine (7.5 micrograms of PRP bound to 125 micrograms of OMP and 5 micrograms of recombinant hepatitis B surface antigen)
Study: 9631980
Drug: benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 20 to 40 mg/day
Study: 2667601
Drug: Spiramycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin (3 X 10(6) iu, twice daily)
Study: 770082
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg azapropazone per day
Study: 31286158
Drug: Electrotherapy, manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrotherapy, manual therapy, and pelvic floor muscle exercises
Study: 21752899
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/d for 6 weeks)
Study: 17144779
Drug: Various strategies
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various strategies for minimizing NSAID risks including low dosages, modified-release and enteric-coated NSAIDs, cyclooxygenase-2-selective inhibitors, monitoring for side effects, and treatments to minimize side effects.
Study: 9107443
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR monotherapy 120 mg
Study: 9107443
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR monotherapy 180 mg
Study: 9107443
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR monotherapy 240 mg
Study: 9107443
Drug: Trandolapril monotherapy
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril monotherapy 0.5 mg
Study: 9107443
Drug: Trandolapril monotherapy
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril monotherapy 2 mg
Study: 9107443
Drug: Trandolapril monotherapy
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril monotherapy 8 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 0.5/120 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 0.5/180 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 0.5/240 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 2/120 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 2/180 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 2/240 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 8/120 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 8/180 mg
Study: 9231890
Drug: Trandolapril/Verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil SR combination 8/240 mg
Study: 9231890
Drug: Mono- and
Normalized name: Mono- and Di-Glycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono- and combination therapy
Study: 7965901
Drug: Fluconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (50 mg once a day for 2 weeks)
Study: 7965901
Drug: Fluconazole plus
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole plus chlorhexidine (chlorhexidine applied twice a day for 2 weeks)
Study: 7965901
Drug: New dentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dentures (no medication)
Study: 3283085
Drug: Mixed-beam radiotherapy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-beam radiotherapy (2 fractions a week of neutrons, 3 fractions a week of photons to a total RBE-adjusted dose of 50 Gy over 5 weeks plus intracavitary applications or external mixed-beam boost)
Study: 29043411
Drug: T‐DM1 (ado-trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐DM1 (ado-trastuzumab emtansine) administered weekly or every three weeks
Study: 16843170
Drug: Rheolytic thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheolytic thrombectomy (RT) as an adjunct to primary percutaneous coronary intervention (PCI)
Study: 15931325
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors in postmenopausal women with invasive or intraductal breast cancer
Study: 15931325
Drug: Targeted molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted molecular therapies such as trastuzumab and bisphosphonates
Study: 27003390
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation program conducted weekly for 5 weeks in 60-min sessions
Study: 19637333
Drug: EcN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN plus mesalamine (1500 mg twice a day)
Study: 12852099
Drug: Oral continuous‐combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous‐combined regimen of conjugated estrogens + medroxyprogesterone acetate
Study: 8598355
Drug: ERT +
Normalized name: Enzyme Replacement Therapy Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT + Mito (IV 12.5 mg/m(2) during the first and fourth week of ERT)
Study: 8598355
Drug: BCNU (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (i.v. 200 mg/m(2) every 6 weeks)
Study: 8598355
Drug: 6-mercaptopurine (6-MP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine (6-MP, 750 mg/m(2) IV daily for 3 days every six weeks)
Study: 6372066
Drug: Trimipramine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine, 50 mg/day
Study: 23092239
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum 299v
Study: 23092239
Drug: Probiotic lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lactobacilli lozenges (L. reuteri DSM 17938 and ATCC PTA 5289)
Study: 23092239
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (probiotic lozenges)
Study: 17240231
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 40 mg vaginally
Study: 15701249
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin ointment (15%) applied twice daily for 30 days
Study: 15701249
Drug: Placebo (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10% urea lotion) applied twice daily for 30 days
Study: 12088953
Drug: Ketamine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.0 mg/kg) with propofol and fentanyl (Group A)
Study: 8951252
Drug: High-frequency oscillatory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency oscillatory ventilation (HFOV) after surfactant administration (100 mg/kg)
Study: 27777261
Drug: Exenatide infusion
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide infusion (n=29)
Study: 21740575
Drug: Daily breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breakfast consumption (≥3000 kJ before 1100 each day)
Study: 12954579
Drug: Ibandronate 6
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 6 mg
Study: 9382122
Drug: Ibandronate 2
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2 mg
Study: 9192194
Drug: Mixed load
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed load (glucose+cream)
Study: 9192194
Drug: Lipids load
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipids load (cream)
Study: 28721080
Drug: Broad-spectrum antibiotic
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotic therapy
Study: 28086005
Drug: Supportive-expressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive therapy
Study: 24859124
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (Control group, n=20)
Study: 19082228
Drug: 2% tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tea lotion
Study: 19082228
Drug: 5% zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% zinc sulphate solution
Study: 15930209
Drug: Morphine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (loading dose of 100 microg/kg, followed by infusions of 10-30 microg/kg per hour)
Study: 15930209
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose infusions)
Study: 12931804
Drug: Extracorporeal shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal shock-wave therapy
Study: 8967584
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (18 mg/kg.h) with fentanyl (0.15 mg)
Study: 8967584
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (18 mg/kg.h) without fentanyl
Study: 8967584
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (18 mg/kg.h)
Study: 1346599
Drug: Thioridazine tablet
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine tablet (5 mg), taken 1 hour after dinner from the 8th to the 18th day of the menstrual cycle.
Study: 6206318
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 to 1.0 mg/day)
Study: 6206318
Drug: Meproscillarin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meproscillarin (0.5 to 2.0 mg/day)
Study: 12658772
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg irbesartan capsule (test)
Study: 12658772
Drug: irbesartan tablet
Normalized name: Irbesartan Tablets
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: irbesartan tablet (reference)
Study: 1673089
Drug: CQA 206‐291
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQA 206‐291 (mixed D1‐D2 receptor agonist)
Study: 7036712
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg cimetidine
Study: 7036712
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg cimetidine
Study: 31866083
Drug: HRT or
Normalized name: Femhrt Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT or oral contraception use
Study: 22858806
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Tacrolimus/Mycophenolate Mofetil/steroids)
Study: 11350323
Drug: Propofol (ED50:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (ED50: 3.45 mg x kg(‐1) x h(‐1), ED95: 6.68 mg x kg(‐1) x h(‐1))
Study: 9346217
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) in combination with carboplatin
Study: 31314569
Drug: Infants receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants receiving ≤4 fl oz daily of formula in the first month
Study: 31314569
Drug: Infants receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants receiving formula daily (not specified volume)
Study: 31314569
Drug: Infants receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants receiving ≤4 fl oz daily of formula